NCT00161707 - Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2003

Primary Completion Date

October 1, 2003

Study Completion Date

October 1, 2003

Conditions

Alpha1-antitrypsin Deficiency

Interventions

DRUG

Aerosolized, Recombinant Alpha 1-Antitrypsin

Trial Locations (4)

Shands Hospital at the University of Florida, Gainesville

Cleveland Clinic Foundation, Department of Pulmonary and Critical Care Medicine, Cleveland

National Jewish Medical and Research Center, Denver

The University of Texas Health Science Center at Tyler, Tyler